Wedbush maintains Tyra Biosciences at Outperform, raises price target to $57 from $53
Wedbush reaffirmed its Outperform rating for Tyra Biosciences and increased its price target to $57 from $53, representing a 7.5% rise. This target suggests a potential 171.4% upside from the Nov 10 closing price of $21, according to the firm.
How this was made

The 30-second read
Why it matters
The main tradable element is the analyst PT increase, which can influence short-term sentiment but does not introduce new operational or clinical information.
Market read
A bullish analyst PT revision may attract incremental speculative interest, but it is unlikely to be a primary driver without new company-specific catalysts.
What to watch
Traders may focus more on upcoming trial/regulatory milestones or broader biotech risk appetite than on a single firm’s PT adjustment.
Background
The piece reports Wedbush’s rating maintenance and a higher price target for Tyra Biosciences.
Ticker impact
Wedbush maintained Tyra Biosciences at Outperform and raised its price target to $57 from $53, implying large upside from the Nov 10 close.
Likely modest upward bias as traders price in the higher target, with follow-through depending on broader biotech sentiment.
The article is an analyst action (PT change) rather than new clinical, regulatory, or financial disclosure; impact is typically limited unless accompanied by new data.
Market effects
Small read-through to biotech sentiment, but no sector-wide catalyst is disclosed.
No specific regional market linkage beyond US biotech sentiment.
No global macro or cross-market linkage mentioned.
Counterpoint
Price-target changes often lag or reflect existing expectations; without new Tyra-specific data, the market may discount the update.
Key entities
- companyTyra Biosciences
Subject of the analyst action, with Wedbush maintaining Outperform and raising the price target to $57.
- analyst_firmWedbush
Brokerage issuing the rating and price-target change.

